As of 2025-12-16, the EV/EBITDA ratio of Esperion Therapeutics Inc (ESPR) is -38.11. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ESPR's latest enterprise value is 1,114.84 mil USD. ESPR's TTM EBITDA according to its financial statements is -29.25 mil USD. Dividing these 2 quantities gives us the above ESPR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.2x - 14.6x | 14.0x |
| Forward P/E multiples | 18.6x - 31.7x | 22.8x |
| Fair Price | (2.50) - (0.36) | (1.56) |
| Upside | -166.2% - -109.6% | -141.2% |
| Date | EV/EBITDA |
| 2025-12-15 | -38.11 |
| 2025-12-12 | -38.68 |
| 2025-12-11 | -40.56 |
| 2025-12-10 | -38.52 |
| 2025-12-09 | -38.19 |
| 2025-12-08 | -39.17 |
| 2025-12-05 | -37.70 |
| 2025-12-04 | -38.19 |
| 2025-12-03 | -38.11 |
| 2025-12-02 | -37.13 |
| 2025-12-01 | -37.62 |
| 2025-11-28 | -39.99 |
| 2025-11-26 | -39.50 |
| 2025-11-25 | -37.38 |
| 2025-11-24 | -33.13 |
| 2025-11-21 | -32.39 |
| 2025-11-20 | -31.33 |
| 2025-11-19 | -30.02 |
| 2025-11-18 | -30.35 |
| 2025-11-17 | -30.27 |
| 2025-11-14 | -30.92 |
| 2025-11-13 | -31.41 |
| 2025-11-12 | -31.98 |
| 2025-11-11 | -32.55 |
| 2025-11-10 | -30.76 |
| 2025-11-07 | -28.96 |
| 2025-11-06 | -27.65 |
| 2025-11-05 | -31.25 |
| 2025-11-04 | -30.51 |
| 2025-11-03 | -31.33 |
| 2025-10-31 | -31.49 |
| 2025-10-30 | -30.43 |
| 2025-10-29 | -30.67 |
| 2025-10-28 | -32.06 |
| 2025-10-27 | -30.92 |
| 2025-10-24 | -29.37 |
| 2025-10-23 | -29.12 |
| 2025-10-22 | -29.45 |
| 2025-10-21 | -30.02 |
| 2025-10-20 | -30.27 |
| 2025-10-17 | -29.69 |
| 2025-10-16 | -28.88 |
| 2025-10-15 | -27.81 |
| 2025-10-14 | -29.29 |
| 2025-10-13 | -29.45 |
| 2025-10-10 | -27.90 |
| 2025-10-09 | -27.28 |
| 2025-10-08 | -28.22 |
| 2025-10-07 | -32.47 |
| 2025-10-06 | -32.72 |